Shanghai, China, Nov 16, 2020 -- Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced today that, after consulting with the U.S.

Shanghai, China, June 18, 2020 -- Kangpu Biopharmaceuticals, a clinical-stage company focused on the discovery and development of next-generation of immunomodulatory small molecules for the treatments of solid tumors, hematological ...

Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human Phase I single ascending dose (SAD) clinical study of KPG-818 conducted in the United States.